| 吴立新.血清miR-378和miR-216b对早期非小细胞肺癌的诊断价值分析[J].浙江中西医结合杂志,2022,32(3): |
| 血清miR-378和miR-216b对早期非小细胞肺癌的诊断价值分析 |
| The diagnostic value of serum miR-378 and miR-216b in early non-small cell lung cancer |
| 投稿时间：2021-07-23 修订日期：2021-12-31 |
| DOI： |
| 中文关键词: 血清miR-378 血清miR-216b 非小细胞肺癌 预后 |
| 英文关键词:Serum miR-378 Serum miR-216b Non-small cell lung cancer Prognosis |
| 基金项目: |
|
| 摘要点击次数: 605 |
| 全文下载次数: 12 |
| 中文摘要: |
| 目的：探讨早期非小细胞肺癌患者血清中miR-378和miR-216b表达水平及其诊断预后价值。方法：前瞻性选择2017年4月至2018年10月我院收治的非小细胞肺癌患者86例（观察组）以及健康体检人员86例（对照组）作为研究对象。采用RT-qPCR检测两组血清中miR-378和miR-216b表达水平。采用ROC曲线评价血清miR-378和miR-216b对早期非小细胞肺癌的诊断价值，Cox回归分析探讨miR-378和miR-216b表达水平是否是早期非小细胞肺癌患者预后的相关因素。结果：观察组血清miR-378表达水平显著高于对照组，miR-216b显著低于对照组（P＜0.05）。手术后，早期非小细胞肺癌患者miR-378水平显著降低，miR-216b水平显著升高（P＜0.05）。ROC曲线结果显示：血清miR-378和miR-216b诊断早期非小细胞肺癌的曲线下面积分别为0.874、0.845，最佳截断值为5.28和4.96，敏感度为81.39%、79.07%，特异度为84.88%、87.20%。血清miR-378高表达和miR-216b低表达患者肿瘤II期、发生淋巴结转移和肿瘤≥3cm）概率显著升高（P＜0.05）。miR-378低表达和miR-216b高表达患者生存率分别大于miR-378高表达和miR-216b低表达患者（P＜0.05）。多因素Cox回归分析显示，肿瘤分期为II期（HR=2.07, 95%CI: 1.28～3.35）、有淋巴转移（HR=3.33, 95%CI:1.55～7.16）、肿瘤大小≥3cm（HR=1.90, 95%CI: 1.11～3.24）、miR-378＞8.13（HR=2.51, 95%CI:1.16～5.44）、miR-216b＜3.61（HR=3.05, 95%CI:1.47～6.32）是影响肺癌患者预后危险因素（P＜0.05）。结论：早期非小细胞肺癌患者血清中miR-378表达水平异常升高、miR-216b表达降低，miR-378异常高表达和miR-216b异常低表达患者预后不良风险增加，miR-378和miR-216b有望作为非小细胞肺癌临床诊治的有效生物标志物 |
| 英文摘要: |
| Objective: To investigate the expression levels of miR-378 and miR-216b in the serum of patients with early non-small cell lung cancer and their diagnostic and prognostic value.. Methods: 86 patients with non-small cell lung cancer (observation group) and 86 healthy physical examiners (control group) admitted to our hospital and its partner units from April 2017 to October 2018 were prospectively selected as research object. RT-qPCR was used to detect the expression levels of miR-378 and miR-216b in the serum of the two groups. ROC curve was used to evaluate the diagnostic value of serum miR-378 and miR-216b for early non-small cell lung cancer. Cox regression analysis was used to investigate whether the expression levels of miR-378 and miR-216b were related factors for the prognosis of patients with early non-small cell lung cancer. Results: The level of serum miR-378 in the observation group was significantly higher than that in the control group, and miR-216b lower than that in the control group (P<0.05). After surgery, the level of miR-378 in patients with early-stage non-small cell lung cancer was significantly reduced, and the level of miR-216b increased (P<0.05). The ROC curve results showed that the area under the curve of serum miR-378 and miR-216b in the diagnosis of early non-small cell lung cancer were 0.874 and 0.845, respectively, the best cut-off values were 5.28 and 4.96, the sensitivity 81.39%, 79.07%, and the specificity 84.88%, 87.20%. In patients with high serum miR-378 expression or low miR-216b expression, the probability of tumor stage II, lymph node metastasis and tumor≥3cm was significantly increased (P<0.05). The survival rates of patients with low miR-378 expression or high miR-216b expression were higher than those with high miR-378 expression and miR-216b low expression respectively (P<0.05). Multivariate Cox regression analysis showed that the tumor stage was stage II (HR=2.07, 95%CI: 1.28～3.35), lymphatic metastasis (HR=3.33, 95%CI: 1.55～7.16), tumor size≥3cm (HR=1.90, 95%CI: 1.11～3.24), miR-378>8.13 (HR=2.51, 95%CI: 1.16～5.44), miR-216b<3.61 (HR=3.05, 95%CI: 1.47～6.32) are the effects Prognostic risk factors for lung cancer patients (P<0.05). Conclusion: The expression level of miR-378 in the serum of patients with early-stage non-small cell lung cancer is abnormally increased, and miR-216b expression is decreased, and patients with abnormally high expression of miR-378 or abnormally low expression of miR-216b have an increased risk of poor prognosis, miR-378 and miR-216b are expected as effective biomarkers for clinical diagnosis and treatment of non-small cell lung cancer |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
